SC
NVCR icon

Syon Capital’s NovoCure NVCR Stock Holding History

Syon Capital’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$307K Sell
20,237
-1,408
-7% -$21.3K 0.01% 787
2026
Q1 		$236K Buy
21,645
+4,194
+24% +$52.4K 0.01% 825
2025
Q4 		$226K Buy
17,451
+3,788
+28% +$48.6K 0.01% 836
2025
Q3 		$177K Sell
13,663
-3,794
-22% -$50.7K 0.01% 794
2025
Q2 		$311K Buy
+17,457
New +$304K 0.02% 535

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Syon Capital's NVCR Position: Q2 2026 in Review

Syon Capital reduced its NovoCure (NVCR) stake by 6.5% in Q2 2026, selling an estimated $21.3K and leaving 20,237 shares worth $307K. The position accounts for 0.01% of the portfolio, ranked #787.

Syon Capital first reported a position in NVCR in Q2 2025 and has held it in 5 quarters since. The position peaked at $311K in Q2 2025. 218 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

  • Syon Capital held 20,237 shares of NovoCure worth $307K as of Q2 2026.
  • Syon Capital sold 1,408 NovoCure shares in Q2 2026, an estimated $21.3K.
  • NovoCure made up 0.01% of Syon Capital's portfolio in Q2 2026, its #787 holding.
  • Syon Capital first reported a position in NovoCure in Q2 2025 and has held it in 5 quarters since.
  • Syon Capital's NovoCure position peaked at $311K in Q2 2025.
  • 218 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on Syon Capital's 13F filing for Q2 2026, filed 14 Aug 2026.